Satish Valluri
About
Satish Valluri is a scholar working on Oncology, Hematology and Immunology.
According to data from OpenAlex, Satish Valluri has authored 37 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 18 papers in Hematology and 8 papers in Immunology. Recurrent topics in Satish Valluri's work include Multiple Myeloma Research and Treatments (16 papers), CAR-T cell therapy research (10 papers) and Protein Degradation and Inhibitors (7 papers). Satish Valluri is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), CAR-T cell therapy research (10 papers) and Protein Degradation and Inhibitors (7 papers). Satish Valluri collaborates with scholars based in United States, Germany and Belgium. Satish Valluri's co-authors include Daniel J. Safer, Julie M. Zito, James F. Gardner, James Korelitz, Jörg M. Fegert, Gerd Glaeske, Katrin Janhsen, Donald R. Mattison, Jack F. Bukowski and Joachim Sieper and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Satish Valluri
35 papers receiving 629 citations
Peers
Satish Valluri
David Rintell United States
Chih‐Cheng Hsiao Taiwan
Sara Dishon Israel
Ben Palmer United Kingdom
Sarah R. Ormseth United States
Alessandro Finkelsztejn Brazil
Louise Heron United Kingdom
Jessica Gonzalez United States
Rod Middleton United Kingdom
Tingjian Yan United States
Citations per year, relative to Satish Valluri Satish Valluri (= 1×)
peers
David Rintell
Countries citing papers authored by Satish Valluri
Since
Specialization
Citations
This map shows the geographic impact of Satish Valluri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satish Valluri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satish Valluri more than expected).
Fields of papers citing papers by Satish Valluri
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Satish Valluri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satish Valluri. The network helps show where Satish Valluri may publish in the future.
Co-authorship network of co-authors of Satish Valluri
This figure shows the co-authorship network connecting the top 25 collaborators of Satish Valluri. A scholar is included among the top collaborators of Satish Valluri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satish Valluri. Satish Valluri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dhakal, Binod, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. Blood Advances. 8(19). 5062–5071.
2.
Yong, Kwee, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials. European Journal of Cancer. 215. 115157–115157.
3.
Dimopoulos, Meletios Α., Pieter Sonneveld, Salomon Manier, et al.. (2024). Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma. BMC Cancer. 24(1). 541–541.
4.
Jagannath, Sundar, Concetta Crivera, Carolyn C. Jackson, et al.. (2023). Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma. Oncology and Therapy. 11(2). 263–275.
5.
Martínez‐López, Joaquín, et al.. (2023). Real-World Treatment Patterns, Healthcare Resource Use and Disease Burden in Patients with Multiple Myeloma in Europe. Future Oncology. 19(31). 2103–2121.
6.
Palmer, Stephen, Yi Lin, Thomas G. Martin, et al.. (2023). Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma. Oncology and Therapy. 11(3). 313–326.
7.
Crawford, Rebecca, Katharine S. Gries, Satish Valluri, et al.. (2022). The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies. Cancer Reports. 5(11). e1603–e1603.
8.
Martin, Thomas, et al.. (2022). EE167 Use of Cost per Responder Models for CAR-T Therapies in Relapsed or Refractory Multiple Myeloma. Value in Health. 25(7). S366–S366.
9.
Weisel, Katja, Amrita Krishnan, Jordan M. Schecter, et al.. (2022). Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 22(9). 690–701.
10.
Martin, Tom, Saad Z. Usmani, Jordan M. Schecter, et al.. (2021). Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Current Medical Research and Opinion. 37(10). 1779–1788.
11.
Shah, Nina, et al.. (2021). Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations. Clinical Drug Investigation. 41(3). 201–210.
12.
Weisel, Katja, Thomas G. Martin, Amrita Krishnan, et al.. (2021). Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Clinical Drug Investigation. 42(1). 29–41.
13.
Martin, Thomas, Amrita Krishnan, Kwee Yong, et al.. (2021). Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 39(15_suppl). 8045–8045.
14.
Costa, Luciano J., Yi Lin, Thomas Martin, et al.. (2021). Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.. Journal of Clinical Oncology. 39(15_suppl). 8030–8030.
15.
Seal, Brian, Sean D. Sullivan, Scott D. Ramsey, et al.. (2013). Systemic Therapy for Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in Nationally Representative US Claims Database. BioDrugs. 28(2). 229–236.
16.
Chastek, Benjamin, Mahesh Kulakodlu, Satish Valluri, & Brian Seal. (2012). CN4 Total Health Care Costs for Colorectal Cancer Patients Following Metastatic Diagnosis. Value in Health. 15(4). A1–A1.
17.
Valluri, Satish, Julie M. Zito, Daniel J. Safer, et al.. (2010). Impact of the 2004 Food and Drug Administration Pediatric Suicidality Warning on Antidepressant and Psychotherapy Treatment for New-Onset Depression. Medical Care. 48(11). 947–954.
18.
Zito, Julie M., Daniel J. Safer, Katrin Janhsen, et al.. (2008). A three-country comparison of psychotropic medication prevalence in youth. Child and Adolescent Psychiatry and Mental Health. 2(1). 26–26.
19.
Zito, Julie M., Daniel J. Safer, Satish Valluri, et al.. (2007). Psychotherapeutic Medication Prevalence in Medicaid-Insured Preschoolers. Journal of Child and Adolescent Psychopharmacology. 17(2). 195–204.
20.
Valluri, Satish, Enrique Seoane‐Vazquez, Rosa Rodríguez-Monguió, & Sheryl L. Szeinbach. (2007). Drug utilization and cost in a Medicaid population: A simulation study of community vs. mail order pharmacy. BMC Health Services Research. 7(1). 122–122.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by David Rintell Breakdown of academic impact, for papers by Chih‐Cheng Hsiao Breakdown of academic impact, for papers by Sara Dishon Breakdown of academic impact, for papers by Ben Palmer Breakdown of academic impact, for papers by Sarah R. Ormseth Breakdown of academic impact, for papers by Alessandro Finkelsztejn Breakdown of academic impact, for papers by Louise Heron Breakdown of academic impact, for papers by Jessica Gonzalez Breakdown of academic impact, for papers by Rod Middleton Breakdown of academic impact, for papers by Tingjian Yan